---
title: "NLS Pharmaceutics (NLSP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NLSP.US.md"
symbol: "NLSP.US"
name: "NLS Pharmaceutics"
industry: "Pharmaceuticals"
datetime: "2026-05-21T12:21:02.520Z"
locales:
  - [en](https://longbridge.com/en/quote/NLSP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NLSP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NLSP.US.md)
---

# NLS Pharmaceutics (NLSP.US)

## Company Overview

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.51 | 75 | - | - | - |
| PB | 1.12 | 50 | 1.12 | 1.12 | 1.12 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NLSP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NLSP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NLSP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NLSP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**